Joel Baglole

Joel Baglole

Joel Baglole has been a financial reporter for more than 20 years. For five years, Mr. Baglole was a staff reporter at The Wall Street Journal, where he wrote articles from Iceland to Indonesia and covered topics ranging from the automotive and airline industries to investment banks and global stock markets.

Mr. Baglole has also worked for The Washington Post and Toronto Star newspapers, and has contributed to business focused websites such as The Motley Fool and Investopedia. At InvestorPlace, he covers a wide range of large and small cap stocks, as well as political and economic issues that impact financial markets.

Check out Joel’s TipRanks profile.

Recent Articles

7 Stocks to Sell When Consumer Confidence Is Falling

There are already signs that consumers are beginning to rollover. According to the U.S. Commerce Department, consumer spending rose a tepid 0.1% in June after falling 0.3% in May. Should things worsen on the consumer front, it could spell bad news for the economy overall, and also for certain stocks.

Why Is Xpeng (XPEV) Stock Down Today?

Shares pf XPEV stock are falling after the Chinese electric vehicle maker reported Q2 results that fell short of Wall Street expectations.

Buy, Sell or Hold? Our Take on the 5 Top Trending Cryptos.

Cryptocurrencies have been clobbered in recent months by numerous bankruptcies and liquidity problems that led to $2 trillion of value being wiped off the market since it peaked last November. Reports that $1.9 billion of cryptocurrency was stolen by hackers in the first seven months of this year also hasn't inspired confidence in the sector.

7 Stocks to Sell Before the Next Black Swan Event

A Black Swan is a rare, catastrophic event that hits the stock market and causes it to crash, unleashing terrible losses for investors. Examples of Black Swan Events include the Black Monday crash of 1987, and the pandemic crash that occurred in March 2020.

Why Is Axsome Therapeutics (AXSM) Stock Up 30% Today?

Biopharmaceutical company AXSM stock is getting a huge lift from news the FDA has approved its depression treatment.